Suppr超能文献

基于胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的围手术期及围操作期管理:叙述性综述以及STOP-GAP和STOP DKA-2算法

Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms.

作者信息

Goldenberg Ronald M, Gilbert Jeremy D, Houlden Robyn L, Khan Tayyab S, Makhija Sapna, Mazer C David, Trinacty Jill, Verma Subodh

机构信息

LMC Diabetes & Endocrinology, Concord, Canada.

Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Toronto, Canada.

出版信息

Curr Med Res Opin. 2025 Mar;41(3):403-419. doi: 10.1080/03007995.2025.2458538. Epub 2025 Jan 31.

Abstract

The GLP-1 receptor-based agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) are major twenty first century breakthroughs in diabetes and obesity medicine but there are important safety considerations regarding the perioperative and periprocedural management of individuals who are treated with these agents. GLP-1RAs have been linked to an increased risk of retained gastric contents and pulmonary aspiration while SGLT2i can be associated with diabetic ketoacidosis. This manuscript provides a narrative review of the available evidence for perioperative and periprocedural risks in people prescribed GLP-1RAs and SGLT2i. The authors provide expert opinion-driven recommendations and algorithms on how to safely manage GLP-1RAs and SGLT2i under perioperative/periprocedural settings.

摘要

基于胰高血糖素样肽-1受体的激动剂(GLP-1RAs)和钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是21世纪糖尿病和肥胖医学领域的重大突破,但对于接受这些药物治疗的个体,在围手术期和围操作期管理方面存在重要的安全考量。GLP-1RAs与胃内容物残留和肺误吸风险增加有关,而SGLT2i可能与糖尿病酮症酸中毒相关。本文对使用GLP-1RAs和SGLT2i的患者围手术期和围操作期风险的现有证据进行了叙述性综述。作者提供了基于专家意见的建议和算法,以指导如何在围手术期/围操作期安全管理GLP-1RAs和SGLT2i。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验